伟德国际victor1946

Milestones-Excellence achieved through unity and diversity. Convergence and condensation result in crystallization.

伟德国际victor1946

Excellence achieved through unity and diversity. Convergence and condensation result in crystallization.

Homepage > About Jingjing > Milestones
2018
The company utilizes core technology to establish new product lines, establishing a new product line, including agmatine, ketoleucine, and aspartate ornithine, further extending the advantageous product chain and forming a product portfolio, taking a solid step toward entering international markets.


2017
The company utilizes core technology to extend strategic products, establishing a new product line, including agmatine, ketoleucine, and aspartate ornithine, further extending the advantageous product chain and forming a product portfolio, taking a solid step toward entering international markets.


2016

The company establishes an academician workstation and national-local joint engineering laboratory, and forms strategic cooperation with Nobel laureate Dr. Murad, dedicated to transforming cutting-edge biomedical technology into achievements, marking a new milestone in the company's journey to become a world-class amino acid enterprise.


2015
The company successfully lists on the National Equities Exchange and Quotations (NEEQ) and enters the innovation tier in the first batch.


2014
The company successfully launches a series of products developed using core technology, including agmatine, ketoleucine, and aspartate ornithine, extending the advantageous product chain and forming a product portfolio, taking a solid step toward entering international markets.


2013
The company obtains high-tech enterprise certification, while wholly-owned subsidiary Shijiazhuang Jingjing Pharmaceutical Co., Ltd. successfully relocates and expands production, becoming one of the first to pass the new version of GMP certification.


2012
With Jingjing Pharmaceutical Co., Ltd. (renamed from Xingtai Ruijingkang Biotechnology Co., Ltd.) as the main entity, integrated and reorganized affiliated companies, increased capital and shares to introduce strategic investors, and transformed into a shareholding company, establishing a standardized corporate governance system.


2010
Shijiazhuang Jingjing Pharmaceutical Co., Ltd. initiates expansion and relocation project to meet market demand.


2009
The fermentation arginine technology independently developed by Xingtai Ruijingkang Biotechnology Co., Ltd. passes Hebei Province scientific achievement evaluation: "This process fills a domestic gap, with overall technology reaching domestic leading and international advanced levels."


2007
Establishment of Xingtai Ruijingkang Biotechnology Co., Ltd., extending the industrial chain upstream.